On September 16, 2021, leading experts from the SITC Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel presented the "SITC Clinical Practice Guideline Webinar – Practical Management Pearls for Immune Checkpoint Inhibitor-related Adverse Events." This high-level webinar covered advanced concepts of toxicity management and risk factors drawing from recommendations within the Clinical Practice Guideline (CPG). The recorded webinar and presentation slides are available below.
The webinar discussed management of toxicities associated with immune checkpoint inhibitor (ICI) therapies and their risk factors, including:
Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org, or check out our free CPG mobile app.
This webinar is supported, in part, by independent medical education grant funding from Amgen and Merck & Co., Inc.The SITC Clinical Practice Guidelines are produced by SITC and have no funding from outside sources.#AdverseEvents #PresentationSlides #RecordedWebinar #ClinicalPracticeGuideline #Clinician#NursePractitioner #Pharmacist #PrimaryCarePhysician #RegisteredNurse #2021
This library resource entry requires a SITC CONNECT account. Click the Sign In button at the top of this page, otherwise click here to create a FREE SITC CONNECT.
With a free SITC CONNET account, you can begin accessing hundreds of cancer immunotherapy resources in the SITC CONNECT Archive and Resource Libraries. Once your account is created, return to this page, refresh, and a download link should appear.
The SITC connectED education portal is supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org